Mobile-health Network Solutions H1 2024 Revenue $6.6M Up From $3M YoY; Expanded Its Headcount And Expenses To Meet Increased Operational Demand And Explore New Market Opportunities, Resulting In An Increase In Net Loss Of $171,634; Cash And Cash...
Mobile-health Network Solutions H1 2024 Revenue $6.6M Up From $3M YoY; Expanded Its Headcount And Expenses To Meet Increased Operational Demand And Explore New Market Opportunities, Resulting In An Increase In Net Loss Of $171,634; Cash And Cash...
The Company expanded its headcount and expenses to meet increased operational demand and explore new market opportunities, resulting in an increase in net loss of $171,634 during H1FY24 as compared to H1FY23.Mobile-health Network Solutions H1 2024 Revenue $6.6M Up From $3M YoY; Expanded Its Headcount And Expenses To Meet Increased Operational Demand And Explore New Market Opportunities, Resulting In An Increase In Net Loss Of $171,634; Cash And Cash Equivalents At December 31, 2023 Was ~$2.5M
移動健康網絡解決方案2024年上半年收入爲660萬美元，高於同比300萬美元；擴大了員工人數和支出以滿足不斷增長的運營需求和探索新的市場機會，淨虧損增加171,634美元；截至2023年12月31日，現金及現金等價物約爲250萬美元
Mobile-health Network Solutions (NASDAQ:MNDR) ("MaNaDr" or "the Company"), a leading Asia-Pacific telehealth provider, today announced that for the first six months of fiscal 2024 ("H1FY24") ended December 31, 2023, the Company had revenue of approximately $6.6 million, approximately a 120% improvement on revenue of $3.0 million for the same period in fiscal 2023 ("H1FY23").
亞太地區領先的遠程醫療提供商移動健康網絡解決方案（納斯達克股票代碼：MNDR）（“ManaDR” 或 “公司”）今天宣佈，在截至2023年12月31日的2024財年（“24財年上半年”）的前六個月中，該公司的收入約爲660萬美元，比2023財年（“23年上半年”）的300萬美元收入增長了約120％。
Telemedicine consultations on the platform increased by approximately 101% during H1FY24, reaching 731,000 compared to 363,000 during H1FY23. The Company believes that this growth was driven by both increased adoption rates and a larger market share. Coupled with the implementation of a dynamic pricing model which increased the average consultation fees, the revenue grew by approximately 120% between H1FY23 and H1FY24. Additionally, the Company improved workflow efficiency for medical professionals by introducing enhancements to the native application, allowing them to focus on core clinical tasks.
在 H1FY24 期間，該平台上的遠程醫療諮詢增加了約101％，達到73.1萬次，相比之下，H1FY23 期間爲36.3萬次。該公司認爲，這種增長是由採用率的提高和市場份額的擴大推動的。再加上動態定價模型的實施提高了平均諮詢費，H1FY23 和 H1FY24 之間的收入增長了約120％。此外，該公司通過引入對本機應用程序的增強功能，提高了醫療專業人員的工作流程效率，使他們能夠專注於核心臨床任務。
The Company's gross profit increased by approximately $0.8 million, or 218% to $1.2 million during H1FY24, mainly due to the 120% increase in revenue and the increase in gross profit margin from 12.7% during H1FY23 to 18.2% during H1FY24.
在 H1FY24 期間，該公司的毛利增長了約80萬美元，增長了218％，達到120萬美元，這主要是由於收入增長了120％，毛利率從H1FY23 的12.7％提高到H1FY24 期間的18.2％。
The Company expanded its headcount and expenses to meet increased operational demand and explore new market opportunities, resulting in an increase in net loss of $171,634 during H1FY24 as compared to H1FY23.
該公司擴大了員工人數和開支，以滿足不斷增長的運營需求和探索新的市場機會，與 H1FY23 相比，H1FY24 期間的淨虧損增加了171,634美元。
Cash and cash equivalents at December 31, 2023, and June 30, 2023, was approximately $2.5 million and $2.2 million, respectively.
截至2023年12月31日和2023年6月30日，現金和現金等價物分別約爲250萬美元和220萬美元。
譯文內容由第三人軟體翻譯。